(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed - 26 Famous Urban communities for Shopping on the planet
- 3Watch live as near-Earth asteroid Eros buzzes the Andromeda Galaxy on Nov. 30 (video)
- 4Early diagnosis leads King Charles to scale back cancer treatment in the new year
- 5Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
- Rick Steves Recommends This German Town's Castle Hotel With Rhine River Views
- Data centers in space: Will 2027 really be the year AI goes to orbit?
- Reports: Germany plans expansion of foreign intelligence powers
- Understanding the Rudiments of Tree Administrations
- Electric Vehicles for Eco-Accommodating Driving
- Sa'ar warns German delegation: 'A Palestinian state would be a Hamas terror state'
- Emergency services search for five people last seen in missing Jeep
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- Easy to understand Tech: Cell phones for Old in 2024
